Brief: Quest Pharmatech says positive interim results from mid-stage clinical study of Oregovomab
29/11/2016 22:03
Nov 29 (Reuters) - Quest Pharmatech Inc QPT.V
* Quest Pharmatech says positive interim results from phase
2b clinical study of Oregovomab
* Quest Pharmatech Inc- Oregovomab in combination with
chemotherapy improves clinical outcome in ovarian cancer
patients
Source text for Eikon: ID:nCNWpPsLqa
Further company coverage: QPT.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Quest PharmaTech
See all newsBrief: Quest Pharmatech Announces Change Of Chief Executive Officer
Brief: Quest Pharmatech Provides Product Development Update
Brief: Quest PharmaTech Clarifies Agreement in Principle with OQP Bio
Brief: Quest Pharmatech Provides Corporate Update
Brief: Quest PharmaTech Announces Sale Of Bioceltran Investment And Return Of Photodynamic Therapy Technology License